Portfolio company
T-CURX
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
3 investors
Sectors
About
This biotech company develops non-viral CAR-T cell therapies to treat patients with leukaemia, lymphoma and solid tumours.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
curocell
This company develops chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory blood cancers such as diffuse large B-cell lymphoma.
Leucid Bio
This biotechnology company develops chimeric antigen receptor T-cell therapies to treat patients with solid tumours and haematological malignancies.
Captain T Cell
The company develops cell therapies for cancer patients to treat solid tumours.
OverT
This biotechnology company develops engineered cell therapies for the treatment of solid tumours in cancer patients.
Swarm Oncology
This biotechnology company develops personalised T cell therapies for patients with advanced solid cancers to achieve long-term remission.
PanCancerT
This biotech company develops T-cell receptor therapies for patients with solid tumours, focusing on targets like triple-negative breast cancer and melanoma.
Autolus Therapeutics
This company develops programmed T-cell therapies for patients with cancer and autoimmune diseases.
ArsenalBio
The company develops programmable T cell therapies for patients with solid tumours and autoimmune diseases.